Identifying New Therapeutic Approaches for Asthma

确定哮喘的新治疗方法

• 批准号: 8344858
• 负责人: Stewart Levine
• 金额: $ 28.4万
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8344858
• 关键词: Adrenal Cortex Hormones; Adverse effects; Agonist; Asthma; Atrophic condition of skin; Bone Density; Breathing; Cataract; Clinical Data; Clinical Trials; Development; Diabetes Mellitus; Disease; Dose; Future; Goals; Host Defense; Human; Hypertension; Myopathy; Oral; Recurrent disease; Refractory; Symptoms; Therapeutic; Tyrosine Kinase Inhibitor; Weight Gain; alternative treatment; asthmatic patient; mTOR Inhibitor; novel therapeutic intervention; pre-clinical; receptor

New treatments are needed for the 5 to 10 % of severe asthmatics who are not well controlled despite treatment with standard therapy. These severe asthmatics have persistent asthma symptoms and recurrent disease exacerbations despite treatment with high-doses of inhaled corticosteroids plus long-acting β2-agonists or oral corticosteroids. In addition, the utilization of oral corticosteroids are associated with serious and potentially debilitating side effects, such as diabetes, hypertension, weight gain, impaired host defense, reduced bone density, cataracts, skin atrophy, and myopathy. Limited alternative treatment options exist for these severe, refractory asthmatics. This project is investigating whether pharmacological agents that are in use for other disorders can be utilized for the treatment of asthma. Current studies are aimed at defining the efficacy of multi-receptor tyrosine kinase inhibitors and mTOR inhibitors for the treatment of asthma. In addition, new therapeutic approaches that are in pre-clinical development may be assessed.

尽管有标准疗法治疗，但仍需要5％至10％的严重哮喘患者中5％至10％的治疗方法。 这些严重的哮喘患者具有持久的哮喘症状和复发性疾病加剧，尽管用高度吸入的皮质类固醇以及长效的β2-激动剂或口服皮质类固醇治疗。 此外，口服皮质类固醇的利用与严重且潜在的衰减副作用有关，例如糖尿病，高血压，体重增加，宿主防御受损，骨密度降低，白内障，皮肤萎缩和肌病。 这些严重的难治性哮喘患者存在有限的替代治疗选择。 该项目正在研究是否可以将用于其他疾病的药理学药物用于治疗哮喘。 当前的研究旨在定义多受体酪氨酸激酶抑制剂和MTOR抑制剂治疗哮喘的功效。 此外，可以评估临床前发育中的新治疗方法。